JavaScript is NOT enabled !

Please enable JavaScript.

Article

PubMed

This record comes from PubMed

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Atherosclerosis. 2018 Oct ; 277 () : 234-255.

ISSN 1879-1484 | 0021-9150
Source

Language English Country Ireland Media print

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link https://www.medvik.cz/link/pmid30270054

PubMed 30270054
DOI 10.1016/j.atherosclerosis.2018.08.051
PII: S0021-9150(18)31359-5
Knihovny.cz E-resources

Keywords
FHSC, Familial hypercholesterolaemia, Primary dyslipidaemia,
MeSH
Anticholesteremic Agents adverse effects therapeutic use MeSH
Biomarkers blood MeSH
Global Health * MeSH
Healthcare Disparities MeSH
Health Services Accessibility MeSH
Phenotype MeSH
Genetic Predisposition to Disease MeSH
Hyperlipoproteinemia Type II blood diagnosis epidemiology therapy MeSH
Cooperative Behavior MeSH
Cholesterol, LDL blood MeSH
Humans MeSH
International Cooperation * MeSH
Predictive Value of Tests MeSH
Prevalence MeSH
Health Care Surveys MeSH
Risk Factors MeSH
Blood Component Removal * adverse effects MeSH
Treatment Outcome MeSH
Check Tag
Humans MeSH
Publication type
Journal Article MeSH
Research Support, Non-U.S. Gov't MeSH
Names of Substances
Anticholesteremic Agents MeSH
Biomarkers MeSH
Cholesterol, LDL MeSH

BACKGROUND AND AIMS: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. METHODS: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. RESULTS: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. CONCLUSIONS: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Find record

Citation metrics

Archiving options